Stocks Health care QGEN
NYSE · Health careQiagen N.V. (QGEN)
Qiagen N.V. reported revenue of $2.1B in fiscal 2025, up 5.7% from a year earlier. Net income was $424.9M, a net margin of 20.3%. Operating cash flow minus capital spending left $453.3M of free cash flow in fiscal 2025. At December 31, 2025 it held $839M in cash against $1.7B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.
Key facts about Qiagen N.V.
- Net worth
- Qiagen N.V. has a market value (market cap) of $10.4B at the latest share price, and shareholders' equity of $3.8B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.1B (+5.7% year on year), with net income of $424.9M.
- Cash flow
- In fiscal 2025 operations brought in $654.3M of cash; after $201M of capital spending, free cash flow was $453.3M.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 20, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
- Dividend
- Qiagen N.V. declared dividends of $0.25 per share in fiscal 2025.
What Qiagen N.V. does
Qiagen N.V. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker QGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.1B | $424.9M | $1.94 | $453.3M |
| 2024 | $2B | $83.6M | $0.37 | $506.4M |
| 2023 | $2B | $341.3M | $1.48 | $309.7M |
| 2022 | $2.1B | $423.2M | $1.84 | $586M |
| 2021 | $2.3B | $512.6M | $2.21 | $449.1M |
| 2020 | $1.9B | $359.2M | $1.53 | $325M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where QGEN ranks in Health care
Dividends
Qiagen N.V. declared $0.25 per share in fiscal 2025. It paid out $54.2M in cash dividends, 13% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.25 | $54.2M | 13% |
| 2024 | n/a | $0 | 0% |
| 2023 | n/a | $0 | 0% |
Latest SEC filings
What Qiagen N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026
- November 6, 2026
- October 28, 2026Form SC TO-C filing SC TO-C
- October 23, 2026
- October 22, 2026Form SC TO-C filing SC TO-C
- October 22, 2026Form SC14D9C filing SC14D9C
- September 9, 2026
- August 7, 2026
- August 7, 2026
Insider trades
What the people running Qiagen N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns QGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Wellington Management Group LLP13G, passive with 3 related filers | 6.5% | February 10, 2026 |
| Massachusetts Financial Services Company13G, passive | 6% | June 5, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 336 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Wellington Management Group Llp | 12,406,763 | -1,957,540 |
| Principal Financial Group Inc | 6,648,681 | +6,643,158 |
| Vanguard Capital Management LLC | 6,209,904 | +103,629 |
| BlackRock, Inc. | 5,905,678 | +655,217 |
| Morgan Stanley | 5,042,391 | +851,478 |
| Earnest Partners LLC | 4,573,455 | +704,966 |
| Goldman Sachs Group Inc | 4,443,674 | +3,052,347 |
| Norges Bank | 4,325,135 | new |
| Millennium Management LLC | 3,845,605 | +3,247,768 |
| Amundi | 3,683,362 | -1,074,319 |
| Marshall Wace, Llp | 3,491,480 | +2,701,482 |
| UBS Group AG | 3,419,195 | +1,990,888 |
| Helikon Investments Ltd | 3,085,155 | +1,277,166 |
| Bank of America Corp | 2,997,617 | -249,356 |
| Dimensional Fund Advisors LP | 2,756,719 | +1,091,708 |
| Fivespan Partners, LP | 2,689,243 | 0 |
| Sei Investments Co | 2,353,350 | +586,568 |
| Allspring Global Investments Holdings, LLC | 2,224,929 | -256,716 |
| Deutsche Bank AG\ | 2,185,808 | -3,416,149 |
| State Street Corp | 2,183,206 | +93,575 |
Insiders
Questions about QGEN
What does Qiagen N.V. do?
Qiagen N.V. is a company in the Health care sector, listed on NYSE as QGEN. Its shares trade on NYSE under the ticker QGEN.
What is Qiagen N.V.'s net worth?
Qiagen N.V. has a market value (market cap) of $10.4B at the latest share price, and shareholders' equity of $3.8B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Qiagen N.V. profitable?
Yes. In fiscal 2025 it reported net income of $424.9M on revenue of $2.1B, a net margin of 20.3%.
How much revenue does Qiagen N.V. make?
In fiscal 2025 Qiagen N.V. reported revenue of $2.1B. That is 5.7% more than a year earlier.
When did Qiagen N.V. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the passive stake changed from November 6, 2026.
Does Qiagen N.V. pay a dividend?
Yes. Qiagen N.V. declared dividends of $0.25 per share in fiscal 2025.
Similar companies
Compare QGEN with
Follow QGEN
Get an email when Qiagen N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Qiagen N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.